ingredients in compound semaglutide Ivím Health US FDA proposes curbs on

These carry specific FDA-approved indications and extensive clinical trial data

Researchers who are not using insulin and who have normal glucose regulation do not face severe hypoglycemia risk from this combination, because both compounds are largely glucose-dependent in their insulin-stimulating effects

More serious but rare risks include pancreatitis, gallbladder disease, and in diabetes patients, potential worsening of diabetic retinopathy (particularly with semaglutide)

Because its a stimulant, the phentermine label warns about increases in blood pressure, insomnia if taken late in the day, and its contraindicated in people with a history of cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, agitated states, or a history of drug abuse

Summary via ACC.org ScienceDaily / Adelaide University

The team will continue studying inequities in GLP-1 access for diabetic and non-diabetic populations, including potential differences by socioeconomic status, race and ethnicity, and Medicare and Medicaid coverage